Skip to content

D&A at other companies

Amgen logo
AmgenAMGN
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$2.5M-66.7%
Operating income-$339.2M-23.6%
Net income-$265.9M-257%
EPS (diluted)-$0.38-265%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%
Free cash flow-$165.1M+4.8%

Valuation

See full
Market cap$26.48B+263%
Enterprise value$25.16B+244%
P/S3,205.4×+2,891×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-9,183.5%-17,093pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Roivant Sciences’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's D&A?
Roivant Sciences (ROIV) reported D&A of $638K in Q1 2026.
How has Roivant Sciences's D&A changed year-over-year?
Roivant Sciences's D&A decreased by 55.2% year-over-year, from $1.43M to $638K.
What is the long-term trend for Roivant Sciences's D&A?
Over 3 years (2022 to 2025), Roivant Sciences's D&A has grown at a -43.8% compound annual growth rate (CAGR), from $18.86M to $3.35M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.